RRC ID 52613
Author Sakamoto Y, Yamagishi S, Tanizawa Y, Tajimi M, Okusaka T, Ojima H.
Title PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay.
Journal Jpn J Clin Oncol
Abstract Biliary tract carcinoma (BTC) is an extremely malignant tumor, but available treatment options are limited. Despite of needs for novel therapies, few BTC-related resources are currently available for evaluation of candidate drugs. To address this issue, we have recently established 13 cell lines from surgical specimens from Japanese BTC patients. In the present study, we evaluated four new molecular targeting agents using our BTC cell-based assay panel with 17 BTC cell lines. PI3K/mTOR dual inhibitor LY3023414 showed activity at submicromolar concentration ranges against 13 of the 17 cell lines tested, including the ones with gemcitabine insensitivity. In conclusion, we demonstrated that in vitro study with the BTC cell line panel would be an efficient approach to screen for novel therapeutic strategies. Although this is preliminary result and further investigations are required for confirmation, PI3K/mTOR inhibitor might be a potential target for BTC drug development.
Volume 48(4)
Pages 396-399
Published 2018-4-1
DOI 10.1093/jjco/hyy011
PII 4883194
PMID 29474549
MeSH Biliary Tract Neoplasms / drug therapy* Biliary Tract Neoplasms / pathology* Cell Line, Tumor Cell Proliferation / drug effects Deoxycytidine / analogs & derivatives Deoxycytidine / pharmacology Deoxycytidine / therapeutic use Gemcitabine Humans Inhibitory Concentration 50 Molecular Targeted Therapy* Phosphatidylinositol 3-Kinases / metabolism* Protein Kinase Inhibitors / therapeutic use Pyridines / pharmacology Pyridines / therapeutic use Quinolones / pharmacology Quinolones / therapeutic use Signal Transduction* / drug effects TOR Serine-Threonine Kinases / metabolism*
IF 2.183
Times Cited 3
Human and Animal Cells TKKK(RCB1907) TGBC24TKB(RCB1196) HuCCT1(RCB1960)